For the quarter ending 2026-03-31, NVAX had -$23,127K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | -9,491 | 17,527 | -202,379 | 625,154 |
| Depreciation and amortization | 3,062 | 5,125 | 6,585 | 15,903 |
| Gain on disposition of novavax cz assets | - | 0 | - | - |
| Right-of-use assets expensed, net of credits received | - | 0 | - | - |
| Impairment of long-lived assets | - | - | - | 349 |
| Non-cash stock-based compensation | 7,724 | 7,967 | 8,549 | 19,499 |
| Provision for excess and obsolete inventory | 0 | 0 | 566 | 1,379 |
| Impairment of assets held for sale | - | 807 | 97,038 | - |
| Impairment of long-lived assets | 266 | 1,498 | 3,382 | - |
| Loss on debt extinguishment | - | 0 | -28,714 | - |
| Other items, net | 8,972 | -1,303 | 229 | -4,682 |
| Inventory | 226 | -2,148 | 3,753 | 1,635 |
| Accounts receivable, prepaid expenses, and other assets | -86,243 | 51,940 | -207,927 | 94,947 |
| Accounts payable, accrued expenses, and other liabilities | -60,078 | -21,543 | -26,535 | -274,488 |
| Deferred revenue | -50,951 | -2,367 | -11,712 | -608,860 |
| Internal-use software | - | 173 | 0 | 655 |
| Net cash used in operating activities | -32,423 | -39,475 | 107,804 | -312,964 |
| Capital expenditures, including internal-use software | 1,270 | 2,076 | 2,017 | 1,467 |
| Proceeds from assets held for sale | 39,750 | 19,653 | - | - |
| Proceeds from disposition of novavax cz assets | - | 0 | - | - |
| Purchases of marketable securities | 214,130 | 95,531 | 235,012 | 114,724 |
| Proceeds from maturities of marketable securities | 147,289 | 98,610 | 100,500 | 154,625 |
| Net cash used in investing activities | -28,361 | 20,483 | -136,529 | 37,779 |
| Net proceeds from sales of common stock | - | 0 | 0 | 0 |
| Proceeds on the issuance of convertible senior notes due 2031, net of issuance costs | - | 0 | 42,606 | - |
| Payments of costs related to issuance of 2027 convertible notes | - | 0 | - | - |
| Proceeds from the exercise of stock-based awards, net of tax withholding | - | -4,798 | - | - |
| Proceeds from credit facility, net of issuance costs | 46,411 | - | - | - |
| Repayment of 2023 convertible notes | - | 0 | - | - |
| Net proceeds from the exercise of stock-based awards, net of tax withholding | -3,690 | - | 820 | -5,288 |
| Finance lease payments | 578 | 6,274 | 984 | 2,813 |
| Net cash provided by (used in) financing activities | 37,675 | -6,604 | 42,442 | -8,101 |
| Effect of exchange rate on cash, cash equivalents, and restricted cash | -18 | -1,709 | 658 | 6,976 |
| Net decrease in cash, cash equivalents, and restricted cash | -23,127 | -27,305 | 14,375 | -276,310 |
| Cash, cash equivalents, and restricted cash at beginning of period | 256,052 | 283,357 | 545,292 | - |
| Cash, cash equivalents, and restricted cash at end of period | 232,925 | 256,052 | 283,357 | - |
NOVAVAX INC (NVAX)
NOVAVAX INC (NVAX)